Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
NanoBioTix (Nasdaq: NBTX) provided its voting rights and share capital update dated October 15, 2025. The company reports 48,237,471 shares outstanding (as of September 30, 2025) and a total theoretical number of voting rights of 50,318,257 with 50,296,139 exercisable voting rights. Markets: Euronext Paris (Compartment B) and NasdaqEuronext. ISIN: FR0011341205. This notice fulfills disclosure requirements under French commercial and AMF rules regarding the number of shares and voting rights.
Nanobiotix (NASDAQ: NBTX) has announced promising first data from a Phase 1 study of JNJ-1900 (NBTXR3) in patients with locally advanced esophageal adenocarcinoma. The study, conducted at MD Anderson Cancer Center, demonstrated an 85% disease control rate and 69% objective response rate among 13 patients.
The treatment, combining JNJ-1900 with chemoradiation, showed strong safety profile and confirmed injection feasibility. Key outcomes include 6 complete responses and 3 partial responses. Of 6 patients who underwent surgery, 2 achieved pathological complete response and 4 showed major pathologic response. The recommended Phase 2 dose was established at 33% of gross tumor volume.
The study continues with recruitment of 17 additional patients, exploring both photon and proton chemoradiation combinations.
Nanobiotix (NASDAQ: NBTX) reported its H1 2025 financial results and business updates, highlighting significant progress in its clinical development program for JNJ-1900 (NBTXR3). The company's revenue increased to €26.6 million, up from €9.3 million in H1 2024, primarily due to a €21.2 million non-cash revenue impact from the J&J agreement amendment.
R&D expenses decreased to €14.5 million from €22.0 million, while net loss improved to €5.4 million from €21.9 million year-over-year. Cash position stood at €28.8 million as of June 30, 2025, expected to fund operations into mid-2026. However, the company noted material uncertainty about its going concern status and is in active discussions for non-dilutive financing to extend its cash runway.
The company achieved several clinical milestones, including the first patient dosing in the CONVERGE study and data announcements from various Phase 1 trials evaluating JNJ-1900 across different cancer types.Nanobiotix (NASDAQ: NBTX) announced updated Phase 1 results for JNJ-1900 (NBTXR3) in combination with anti-PD-1 therapy for head and neck cancer patients. The study showed promising outcomes in both anti-PD-1 naïve and resistant patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC).
Key findings include a 63% disease control rate and 37% objective response rate in anti-PD-1 naïve patients, while resistant patients showed a 74% disease control rate and 32% objective response rate. The treatment demonstrated strong local control with a 95% aggregate disease control rate in injected lesions across all evaluable patients. Median overall survival reached 15.5 months for naïve patients and 11.4 months for resistant patients.
The treatment was well-tolerated among 103 heavily pre-treated patients, with investigators concluding these promising results warrant further exploration in randomized controlled trials.
Nanobiotix (NASDAQ: NBTX) has announced promising new results from a Phase 1 study of JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors for treating primary cutaneous melanoma resistant to anti-PD-1. The study showed a 47.4% objective response rate and 78.9% disease control rate in all lesions per RECIST 1.1.
Key findings include a median Overall Survival of 14.6 months and establishment of the recommended phase 2 dose at 33% of gross tumor volume. The treatment demonstrated a favorable safety profile, with only 5 patients experiencing treatment-related adverse events. Notably, in JNJ-1900 injected & irradiated tumors, researchers observed a 100% disease control rate.
Nanobiotix (NASDAQ:NBTX) has released its monthly update on voting rights and share capital as of August 31, 2025. The company reported 48,236,771 shares outstanding, with 50,337,954 theoretical voting rights and 50,315,836 exercisable voting rights.
This disclosure is made in compliance with French regulatory requirements, as the company is listed on both Euronext Paris and Nasdaq.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management team, including CEO Laurent Levy and CFO Bart van Rhijn, will participate in a fireside chat on Tuesday, September 9th, 2025, at 9:00 am EDT. The presentation will be accessible via webcast on the company's investor relations website, with a replay available after the event.
Nanobiotix (NASDAQ: NBTX) has reported its latest voting rights and share capital status as of July 31, 2025. The company disclosed a total of 48,236,671 shares outstanding, with 50,340,736 theoretical voting rights and 50,318,618 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, with dual listings on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix (NASDAQ: NBTX) announced two significant developments for its radioenhancer JNJ-1900 (NBTXR3). First, major European health authorities have reclassified the product from a medical device to a medicinal product, aligning with its status in the US and other major markets. This reclassification follows updated insights into the product's mechanism of action.
Second, the company has filed a new composition of matter patent for JNJ-1900, which is currently licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company. The product is undergoing extensive global clinical development, including a pivotal Phase 3 trial in head and neck cancer, across multiple tumor types and therapeutic combinations.